LOBEFARO, RICCARDO
LOBEFARO, RICCARDO
Universita' degli Studi di MILANO
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors
2023 E. Zattarin, L. Mariani, A. Menichetti, R. Leporati, L. Provenzano, F. Ligorio, G. Fucà, R. Lobefaro, L. Lalli, A. Vingiani, F. Nichetti, G. Griguolo, M. Sirico, O. Bernocchi, A. Marra, C. Corti, P. Zagami, E. Agostinetto, F. Jacobs, P. Di Mauro, D. Presti, C. Sposetti, C.A. Giorgi, V. Guarneri, R. Pedersini, A. Losurdo, D. Generali, G. Curigliano, G. Pruneri, F. de Braud, M.V. Dieci, C. Vernieri
Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial
2022 F. Ligorio, G. Fucà, L. Provenzano, R. Lobefaro, L. Zanenga, A. Vingiani, A. Belfiore, A. Lorenzoni, A. Alessi, G. Pruneri, F. de Braud, C. Vernieri
Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin
2022 E. Zattarin, F. Nichetti, F. Ligorio, L. Mazzeo, R. Lobefaro, G. Fuca, G. Peverelli, A. Vingiani, G. Bianchi, V, G. Capri, F. de Braud, C. Vernieri
PillarX: A Microfluidic Device to Profile Circulating Tumor Cell Clusters Based on Geometry, Deformability, and Epithelial State
2022 B.J. Green, M. Marazzini, B. Hershey, A. Fardin, Q. Li, Z. Wang, G. Giangreco, F. Pisati, S. Marchesi, A. Disanza, E. Frittoli, E. Martini, S. Magni, G.V. Beznoussenko, C. Vernieri, R. Lobefaro, D. Parazzoli, P. Maiuri, K. Havas, M. Labib, S. Sigismund, P.P.D. Fiore, R.H. Gunby, S.O. Kelley, G. Scita
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology
2022 S. Manglaviti, M. Brambilla, D. Signorelli, R. Ferrara, G. Lo Russo, C. Proto, G. Galli, A. De Toma, M. Occhipinti, G. Viscardi, T. Beninato, E. Zattarin, M. Bini, R. Lobefaro, G. Massa, A. Bottiglieri, G. Apollonio, E. Sottotetti, R.M. Di Mauro, B. Trevisan, M. Ganzinelli, A. Fabbri, F.G.M. de Braud, M.C. Garassino, A. Prelaj
Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape
2021 G. Salvadori, F. Zanardi, F. Iannelli, R. Lobefaro, C. Vernieri, V.D. Longo
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program
2021 A. Prelaj, A. Bottiglieri, C. Proto, G. Lo Russo, D. Signorelli, R. Ferrara, G. Galli, A. De Toma, G. Viscardi, M. Brambilla, R. Lobefaro, F. Nichetti, S. Manglaviti, M. Occhipinti, A. Labianca, M. Ganzinelli, R. Gallucci, N. Zilembo, G.F. Greco, V. Torri, F. de Braud, M.C. Garassino
Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer
2021 F. Ligorio, I. Pellegrini, L. Castagnoli, A. Vingiani, R. Lobefaro, E. Zattarin, M. Santamaria, S.M. Pupa, G. Pruneri, F. de Braud, C. Vernieri
The pan-immune-inflammation-value predicts the survival of patients with human epidermal growth factor receptor 2 (Her2)—positive advanced breast cancer treated with first-line taxane-trastuzumab-pertuzumab
2021 F. Ligorio, G. Fuca, E. Zattarin, R. Lobefaro, L. Zambelli, R. Leporati, C. Rea, G. Mariani, G.V. Bianchi, G. Capri, F. de Braud, C. Vernieri
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers
2021 R. Lobefaro, G. Viscardi, R. Di Liello, G. Massa, M.L. Iacovino, F. Sparano, C.M. Della Corte, R. Ferrara, D. Signorelli, C. Proto, A. Prelaj, G. Galli, A. De Toma, M. Brambilla, M. Ganzinelli, B. Trevisan, F. Ciardiello, F. De Braud, F. Morgillo, M.C. Garassino, G. Lo Russo
Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer
2020 C. Vernieri, M. Prisciandaro, F. Nichetti, R. Lobefaro, G. Peverelli, F. Ligorio, E. Zattarin, M.S. Cona, P. Sepe, F. Corti, S. Manglaviti, M. Brambilla, B. Re, A. Belfiore, G. Pruneri, L. Celio, G. Mariani, G.V. Bianchi, L. Rivoltini, G. Capri, F. de Braud
Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications
2020 E. Zattarin, R. Leporati, F. Ligorio, R. Lobefaro, A. Vingiani, G. Pruneri, C. Vernieri
Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma : Myth or Reality?
2020 E. Dell'Aquila, T. Zeppola, M. Stellato, F. Pantano, M. Scartozzi, C. Madaudo, F. Pietrantonio, C. Cremolini, G. Aprile, B. Vincenzi, R. Moretto, M. Puzzoni, S. Garattini, R. Lobefaro, G. Tonini, D. Santini
Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysis
2020 R. Lobefaro, E. Zattarin, F. Nichetti, M. Prisciandaro, F. Ligorio, M. Brambilla, P. Sepe, F. Corti, G. Peverelli, A. Ottini, T. Beninato, L. Mazzeo, C.G. Rea, G. Mariani, F. de Braud, G.V. Bianchi, C. Vernieri, G. Capri
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
2019 F. Pietrantonio, R. Lobefaro, M. Antista, S. Lonardi, A. Raimondi, F. Morano, S. Mosconi, L. Rimassa, S. Murgioni, A. Sartore-Bianchi, G. Tomasello, R. Longarini, G. Farina, F. Petrelli, S. Gori, G. Randon, S. Corallo, F. Pagani, V. Guarini, F. Palermo, A. Martinetti, M. Macagno, L. Barault, F. Perrone, E. Tamborini, M. Milione, F. Di Nicolantonio, M. Di Maio, G. Fucà, M. Di Bartolomeo, F. de Braud
The landscape of actionable gene fusions in colorectal cancer
2019 F. Pagani, G. Randon, V. Guarini, A. Raimondi, M. Prisciandaro, R. Lobefaro, M. Di Bartolomeo, G. Sozzi, F. de Braud, P. Gasparini, F. Pietrantonio
“Systemic strategy at the patient’s service”: A congress report on supportive care in oncology
2017 F. Nichetti, R. Lobefaro, F. Pagani, G. Randon, F. Corti, F.G.M. DE BRAUD, L. Celio, M. Platania